Literature DB >> 2157300

Ischemia-induced neutrophil activation and diapedesis is lipoxygenase dependent.

G Goldman1, R Welbourn, I S Paterson, J M Klausner, L Kobzik, C R Valeri, D Shepro, H B Hechtman.   

Abstract

Ischemia and reperfusion lead to eicosanoid- and neutrophil (PMN)-dependent injury. This study tests the role of ischemia-induced lipoxygenase activity in mediating PMN activation and diapedesis. Anesthetized rabbits (n = 8) underwent 3 hours of bilateral hindlimb ischemia. At 10 minutes of reperfusion, leukotriene B4 (LTB4) levels in femoral venous effluent were 0.49 +/- 0.05 ng/ml compared with 0.04 +/- 0.07 ng/ml in sham-treated animals (n = 10) (p less than 0.05). Intracellular H2O2 production of circulating PMNs assayed flow cytometrically by dichlorofluorescein (DCF) oxidation, increased from a preischemic value of 74 +/- 14 femtomoles DCF/cell to 135 +/- 8 fmol DCF/cell (p less than 0.05). PMNs were treated with phorbol myristate acetate (PMA), 10(-7) mol/L. In contrast to a 162% increase in H2O2 production before ischemia, PMNs at 10 minutes of reperfusion had an enhanced response to PMA of 336% (p less than 0.05). Addition of authentic LTB4 (0.5 ng/ml) to PMN from sham-treated animals led to their activation, manifest by an oxidative burst, 127 +/- 12 fmol DCF/cell, and an enhanced response of 337% to PMA stimulation. To study diapedesis, plasma collected at 10 minutes of reperfusion was introduced into plastic chambers taped atop skin abrasions in rabbits (n = 8). After 3 hours, 1610 +/- 246 PMN/mm3 accumulated and LTB4 levels in blister fluid were 0.83 +/- 0.03 ng/ml, higher than values of 44 +/- 23 PMN/mm3 (p less than 0.05) and 0.04 +/- 0.03 ng LTB4/ml (p less than 0.05) with saline solution and 68 +/- 16 PMN/mm3 (p less than 0.05) and 0.19 +/- 0.02 ng/ml (p less than 0.05) with nonischemic plasma. The introduction of LTB4, 3.3 ng/ml, into the chambers resulted in an accumulation of 536 +/- 352 PMN/mm3 (p less than 0.05). Pretreatment of animals before hindlimb ischemia (n = 5) with the lipoxygenase inhibitor diethylcarbamazine abolished PMN activation (51 +/- 12 fmol DCF/cell) and ischemic plasma-induced diapedesis into the plastic chamber (38 +/- 18 PMN/mm3). Pretreatment of nonischemic animals (n = 13) used for the dermabrasion bioassay with diethylcarbamazine abolished diapedesis into the plastic chambers induced by ischemic plasma (n = 5) (32 +/- 24 PMN/mm3) or LTB4 (n = 3) (36 +/- 28 PMN/mm3). These data indicate that PMN activation after reperfusion of ischemic tissue is mediated by a lipoxygenase product, perhaps LTB4, and that both reperfusion plasma and authentic LTB4 induce diapedesis by stimulating de novo lipoxygenase activity.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2157300

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  5 in total

1.  Leukotrienes as mediators in ischemia-reperfusion injury in a microcirculation model in the hamster.

Authors:  H A Lehr; A Guhlmann; D Nolte; D Keppler; K Messmer
Journal:  J Clin Invest       Date:  1991-06       Impact factor: 14.808

Review 2.  A hypothesis for the cause of complex regional pain syndrome-type I (reflex sympathetic dystrophy): pain due to deep-tissue microvascular pathology.

Authors:  Terence J Coderre; Gary J Bennett
Journal:  Pain Med       Date:  2010-08       Impact factor: 3.750

3.  Requirements for neutrophil products and L-arginine in ischemia-reperfusion injury.

Authors:  A Seekamp; M S Mulligan; G O Till; P A Ward
Journal:  Am J Pathol       Date:  1993-04       Impact factor: 4.307

4.  Inhibition of superoxide production in human neutrophils by combinations of heparin and thrombolytic agents.

Authors:  K Riesenberg; F Schlaeffer; A Katz; R Levy
Journal:  Br Heart J       Date:  1995-01

5.  Cooperative role of endogenous leucotrienes and platelet-activating factor in ischaemia-reperfusion-mediated tissue injury.

Authors:  Claudia S Bitencourt; Valérie L Bessi; David N Huynh; Liliane Ménard; Julie S Lefebvre; Tania Lévesque; Leila Hamdan; Fanny Sohouhenou; Lucia H Faccioli; Pierre Borgeat; Sylvie Marleau
Journal:  J Cell Mol Med       Date:  2013-11-01       Impact factor: 5.310

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.